{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T19:08:23Z","timestamp":1774465703963,"version":"3.50.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.ygyno.2021.08.011","type":"journal-article","created":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T23:20:09Z","timestamp":1629760809000},"page":"427-432","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["TCGA molecular subgroups of endometrial carcinoma in ovarian endometrioid carcinoma: A quantitative systematic review"],"prefix":"10.1016","volume":"163","author":[{"given":"Nicoletta","family":"D'Alessandris","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Travaglino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damiano","family":"Arciuolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Scaglione","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Raffone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frediano","family":"Inzani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gian Franco","family":"Zannoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ygyno.2021.08.011_bb0005","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.ajpath.2015.11.011","article-title":"The dualistic model of ovarian carcinogenesis: revisited, revised, and expanded","volume":"186","author":"Kurman","year":"2016","journal-title":"Am. J. Pathol."},{"issue":"12","key":"10.1016\/j.ygyno.2021.08.011_bb0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0050232","article-title":"Ovarian carcinoma subtypes are different diseases: implications for biomarker studies","volume":"5","author":"Kobel","year":"2008","journal-title":"PLoS Med."},{"key":"10.1016\/j.ygyno.2021.08.011_bb0015","article-title":"Female Genital Tumours","volume":"4","author":"WHO Classification of Tumours Editorial Board","year":"2020"},{"issue":"1","key":"10.1016\/j.ygyno.2021.08.011_bb0020","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/uog.8970","article-title":"Ovarian cancer arising in endometrioid cysts: ultrasound findings","volume":"38","author":"Testa","year":"2011","journal-title":"Ultrasound Obstet. Gynecol."},{"issue":"1","key":"10.1016\/j.ygyno.2021.08.011_bb0025","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1186\/s12957-016-1054-7","article-title":"Endometriosis-associated clear cell carcinoma arising in caesarean section scar: a case report and review of the literature","volume":"14","author":"Ferrandina","year":"2016","journal-title":"World J. Surg. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2021.08.011_bb0030","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00428-014-1599-1","article-title":"Mutational status of KRAS, NRAS, and BRAF in primary clear cell ovarian carcinoma","volume":"465","author":"Zannoni","year":"2014","journal-title":"Virchows Arch."},{"key":"10.1016\/j.ygyno.2021.08.011_bb0035","first-page":"1","article-title":"The many faces of endometriosis-related neoplasms in the same patient: a brief report [published online ahead of print, 2020 Jun 22]","author":"Santoro","year":"2020","journal-title":"Gynecol. Obstet. Investig."},{"issue":"1","key":"10.1016\/j.ygyno.2021.08.011_bb0040","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/modpathol.2013.107","article-title":"Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles","volume":"27","author":"McConechy","year":"2014","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ygyno.2021.08.011_bb0045","doi-asserted-by":"crossref","DOI":"10.1007\/s00428-020-02760-5","article-title":"Aberrant non-canonical WNT pathway as key-driver of high-grade serous ovarian cancer development","author":"Zannoni","year":"2020","journal-title":"Virchows Arch."},{"issue":"3","key":"10.1016\/j.ygyno.2021.08.011_bb0050","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/humupd\/dmz047","article-title":"Cancer-associated mutations in endometriosis: shedding light on the pathogenesis and pathophysiology","volume":"26","author":"Guo","year":"2020","journal-title":"Hum. Reprod. Update"},{"issue":"7447","key":"10.1016\/j.ygyno.2021.08.011_bb0055","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Cancer Genome Atlas Research Network","year":"2013","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.ygyno.2021.08.011_bb0060","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ygyno.2019.08.019","article-title":"TCGA molecular groups of endometrial cancer: pooled data about prognosis","volume":"155","author":"Raffone","year":"2019","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2021.08.011_bb0065","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/ijgc-2020-002230","article-title":"ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma","volume":"31","author":"Concin","year":"2021","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2021.08.011_bb0070","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.3390\/cancers13112623","article-title":"New pathological and clinical insights in endometrial cancer in view of the updated ESGO\/ESTRO\/ESP guidelines","volume":"13","author":"Santoro","year":"2021","journal-title":"Cancers"},{"issue":"7353","key":"10.1016\/j.ygyno.2021.08.011_bb0075","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Cancer Genome Atlas Research Network","year":"2011","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.ygyno.2021.08.011_bb0080","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1038\/modpathol.2017.81","article-title":"Molecular-based classification algorithm for endometrial carcinoma categorizes ovarian endometrioid carcinoma into prognostically significant groups","volume":"30","author":"Parra-Herran","year":"2017","journal-title":"Mod. Pathol."},{"issue":"3","key":"10.1016\/j.ygyno.2021.08.011_bb0085","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ygyno.2019.07.012","article-title":"Molecular profiling and molecular classification of endometrioid ovarian carcinomas","volume":"154","author":"Cybulska","year":"2019","journal-title":"Gynecol. Oncol."},{"issue":"20","key":"10.1016\/j.ygyno.2021.08.011_bb0090","doi-asserted-by":"crossref","first-page":"5400","DOI":"10.1158\/1078-0432.CCR-20-1268","article-title":"Endometrial cancer molecular risk stratification is equally prognostic for endometrioid ovarian carcinoma","volume":"26","author":"Kr\u00e4mer","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.ygyno.2021.08.011_bb0095","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1097\/PAS.0000000000001478","article-title":"Molecular heterogeneity of endometrioid ovarian carcinoma: an analysis of 166 cases using the endometrial cancer subrogate molecular classification","volume":"44","author":"Leskela","year":"2020","journal-title":"Am. J. Surg. Pathol."},{"issue":"1","key":"10.1016\/j.ygyno.2021.08.011_bb0100","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ygyno.2020.01.008","article-title":"Histopathological characterization of ProMisE molecular groups of endometrial cancer","volume":"157","author":"Raffone","year":"2020","journal-title":"Gynecol. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2021.08.011_bb0105","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s00404-021-06028-4","article-title":"Clinical features of ProMisE groups identify different phenotypes of patients with endometrial cancer","volume":"303","author":"Raffone","year":"2021","journal-title":"Arch. Gynecol. Obstet."},{"issue":"5","key":"10.1016\/j.ygyno.2021.08.011_bb0110","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1007\/s00404-020-05531-4","article-title":"TCGA molecular subgroups and FIGO grade in endometrial endometrioid carcinoma","volume":"301","author":"Travaglino","year":"2020","journal-title":"Arch. Gynecol. Obstet."},{"key":"10.1016\/j.ygyno.2021.08.011_bb0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst. Rev."},{"issue":"2","key":"10.1016\/j.ygyno.2021.08.011_bb0120","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/bjc.2015.190","article-title":"A clinically applicable molecular-based classification for endometrial cancers","volume":"113","author":"Talhouk","year":"2015","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.ygyno.2021.08.011_bb0125","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/cncr.30496","article-title":"Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer","volume":"123","author":"Talhouk","year":"2017","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.ygyno.2021.08.011_bb0130","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/annonc\/mdy058","article-title":"Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series","volume":"29","author":"Kommoss","year":"2018","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2021.08.011_bb0135","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ygyno.2017.10.037","article-title":"An NRG oncology\/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer","volume":"148","author":"Cosgrove","year":"2018","journal-title":"Gynecol. Oncol."},{"issue":"16","key":"10.1016\/j.ygyno.2021.08.011_bb0140","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1158\/1078-0432.CCR-15-2878","article-title":"Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer-combined analysis of the PORTEC cohorts","volume":"22","author":"Stelloo","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.ygyno.2021.08.011_bb0145","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/PAS.0000000000001020","article-title":"Molecular classification of grade 3 endometrioid endometrial cancers identifies distinct prognostic subgroups","volume":"42","author":"Bosse","year":"2018","journal-title":"Am. J. Surg. Pathol."},{"issue":"8","key":"10.1016\/j.ygyno.2021.08.011_bb0150","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann. Intern. Med."},{"issue":"3","key":"10.1016\/j.ygyno.2021.08.011_bb0155","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.ygyno.2019.03.100","article-title":"Molecular markers in recurrent stage I, grade 1 endometrioid endometrial cancers","volume":"153","author":"Moroney","year":"2019","journal-title":"Gynecol. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2021.08.011_bb0160","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/modpathol.2015.43","article-title":"Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative","volume":"28","author":"Stelloo","year":"2015","journal-title":"Mod. Pathol."},{"issue":"3","key":"10.1016\/j.ygyno.2021.08.011_bb0165","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.ygyno.2011.05.025","article-title":"Cytoplasmic expression of estrogen receptor beta (ER\u03b2) predicts poor clinical outcome in advanced serous ovarian cancer","volume":"122","author":"De Stefano","year":"2011","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2021.08.011_bb0170","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.gene.2014.03.037","article-title":"Sox9 and Hif-2\u03b1 regulate TUBB3 gene expression and affect ovarian cancer aggressiveness","volume":"542","author":"Raspaglio","year":"2014","journal-title":"Gene"},{"issue":"1","key":"10.1016\/j.ygyno.2021.08.011_bb0175","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00280-010-1462-2","article-title":"Hyaluronic acid-paclitaxel: effects of intraperitoneal administration against CD44(+) human ovarian cancer xenografts","volume":"68","author":"De Stefano","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"9","key":"10.1016\/j.ygyno.2021.08.011_bb0180","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1158\/1078-0432.CCR-03-0524","article-title":"Frequent loss of pRb2\/p130 in human ovarian carcinoma","volume":"10","author":"D\u2019Andrilli","year":"2004","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.ygyno.2021.08.011_bb0185","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/annonc\/mdw007","article-title":"Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: a retrospective longitudinal analysis using matched tumor biopsies","volume":"27","author":"Petrillo","year":"2016","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2021.08.011_bb0190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060145","article-title":"Expression of the glioma-associated oncogene homolog 1 (gli1) in advanced serous ovarian cancer is associated with unfavorable overall survival","volume":"8","author":"Ciucci","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.ygyno.2021.08.011_bb0195","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ygyno.2013.12.027","article-title":"Prognostic significance of the estrogen receptor beta (ER\u03b2) isoforms ER\u03b21, ER\u03b22, and ER\u03b25 in advanced serous ovarian cancer","volume":"132","author":"Ciucci","year":"2014","journal-title":"Gynecol. Oncol."},{"issue":"22","key":"10.1016\/j.ygyno.2021.08.011_bb0200","doi-asserted-by":"crossref","first-page":"18966","DOI":"10.18632\/oncotarget.3943","article-title":"Role and prognostic significance of the epithelial-mesenchymal transition factor ZEB2 in ovarian cancer","volume":"6","author":"Prislei","year":"2015","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.ygyno.2021.08.011_bb0205","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.humpath.2011.05.002","article-title":"Prognostic role of metastasis tumor antigen 1 in patients with ovarian cancer: a clinical study","volume":"43","author":"Prisco","year":"2012","journal-title":"Hum. Pathol."},{"issue":"2","key":"10.1016\/j.ygyno.2021.08.011_bb0210","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ygyno.2018.09.001","article-title":"Genomics to immunotherapy of ovarian clear cell carcinoma: unique opportunities for management","volume":"151","author":"Oda","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.08.011_bb0215","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/annonc\/mdz062","article-title":"ESMO\u2013ESGO consensus conference, recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease","volume":"30","author":"Colombo","year":"2019","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2021.08.011_bb0220","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/his.13976","article-title":"Clear cell endometrial carcinoma and the TCGA classification","volume":"76","author":"Travaglino","year":"2020","journal-title":"Histopathology"},{"issue":"12","key":"10.1016\/j.ygyno.2021.08.011_bb0225","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1097\/PAS.0000000000001328","article-title":"p53, mismatch repair protein, and POLE abnormalities in ovarian clear cell carcinoma: an outcome-based clinicopathologic analysis","volume":"43","author":"Parra-Herran","year":"2019","journal-title":"Am. J. Surg. Pathol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821013093?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821013093?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:59:50Z","timestamp":1758772790000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825821013093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S0090825821013093"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.08.011","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TCGA molecular subgroups of endometrial carcinoma in ovarian endometrioid carcinoma: A quantitative systematic review","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.08.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}